Portfolio company
HistoSonics
United States
Raised
Undisclosed
Latest stage
Series A
Rounds recorded
1 · 1 undisclosed
Backed by
3 investors
Sectors
About
HistoSonics develops a non-invasive sonic beam therapy platform for the mechanical destruction of liver and kidney tumours for healthcare providers and physicians.
SourceFunding history · 1
Similar companies
Petal Surgical
The company develops an incisionless surgical platform using millisecond pulse histotripsy and robotics to provide non-invasive tissue treatment for healthcare providers and patients.
TRANSURETHRAL IMAGING & THERAPY
This company develops a transurethral ultrasound imaging and high-intensity focused ultrasound therapy system for urologists to treat prostate disease in outpatient procedures.
Sonothera Therapeutics
This company develops a non-viral gene therapy platform using ultrasound and microbubbles to deliver genetic medicines for patients with serious diseases.
Applaud Medical
This company develops microbubble ultrasound technology to break up ureteral stones for patients without the need for routine anesthesia or stents.
Oncoustics
This company develops AI-powered software that analyses raw ultrasound signals for non-invasive liver disease diagnostics and tissue characterisation for clinics and pharmaceutical partners.
HEPTA Medical
This company develops a microwave ablation platform with integrated temperature sensors for clinicians to treat early-stage lung cancer patients using minimally invasive procedures.
SonoThera™
This company develops an ultrasound-guided non-viral platform to deliver genetic medicines for patients with chronic and rare diseases.
SoniVie
SoniVie develops ultrasound-based intravascular denervation systems to treat patients with hypertensive disorders, including resistant hypertension and pulmonary arterial hypertension.
